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تأثري األمراض املصاحبة على البقاء على قيد احلياة بني مرضى سرطان الدم 
النخاعي املزمن باستخدام معيار تشارلسون لالعتالل املشرتك
دراسة استعادية من البصرة، العراق
ون، �أ�صعد خلف، �إيالف �صالح ون ح�صُّ ر�فد  َعبُّود، ح�صُّ
abstract: Objectives: In chronic diseases, comorbidities are known to have a strong negative association with overall 
survival (OS). This study aimed to use the Charlson Comorbidity Index (CCI) to examine the effect of comorbidities 
on OS among patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors. Methods: This 
retrospective study was conducted between January 2006 and October 2016 and included 247 CML patients treated at 
the Basra Oncology & Haematology Centre, Basra, Iraq. Information from hospital records was used to calculate CCI 
scores and patients were divided into groups based on scores of 2–3 (CCI1 group) or ≥4 (CCI2 group). The OS was 
calculated using Kaplan-Meier curves. Results: There were 177 (71.7%) patients in the CCI1 group and 70 (28.3%) in 
the CCI2 group. Overall, patients in the CCI1 group were significantly younger compared to those in the CCI2 group 
(median age: 35 versus 60 years; P <0.001); however, the gender distribution was similar in both groups (male-to-female 
ratio of 1:1.06 versus 1:1.18, respectively; P = 0.683). Diabetes mellitus was the most common comorbidity (17%), 
followed by hypertension (12%) and gastrointestinal diseases (6%). There were no significant differences in mortality 
between the groups (9.6% versus 8.6%; P = 0.801). In total, 69.6% of all deaths were related to CML progression rather 
than to the presence of comorbidities. Conclusion: No significant correlation was found between CCI score and OS 
among CML patients in Basra. However, larger long-term prospective studies are needed to evaluate associations with 
median age at diagnosis and disease severity and to develop region-specific prognostic scales.
Keywords: Comorbidity; Chronic Myeloid Leukemia; Mortality; Survival Analysis; Chronic Diseases; Iraq.
امللخ�ص: الهدف: من �ملعروف �أنه يف �الأمر��س �ملزمنة يكون لالأمر��س �مل�صاحبة �رتباط �صلبي قوي مع �لبقاء على قيد �حلياة ب�صكل 
عام. تهدف هذه �لدر��صة �إىل ��صتخد�م معيار ت�صارل�صون لالعتالل �مل�صرتك لفح�س تاأثري �الأمر��س �مل�صاحبة على �لبقاء على قيد �حلياة 
ب�صكل عام بني مر�صى �رصطان �لدم �لنخاعي �ملزمن �لذين عوجلو� مبثبطات �لتريوزين كيناز. الطريقة: �أجريت هذه �لدر��صة �ال�صتعادية بني 
يناير 2006 و�أكتوبر 2016 و�صملت 247 من مر�صى �رصطان �لدم �لنخاعي �ملزمن و�لذين عوجلو� يف مركز �لب�رصة لالأور�م و�أمر��س �لدم، 
�لب�رصة، �لعر�ق. مت ��صتخد�م �ملعلومات يف �صجالت �مل�صت�صفى الحت�صاب جمموع نقاط معيار ت�صارل�صون لالعتالل �مل�صرتك ومت تق�صيم 
�ملر�صى �إىل جمموعات على �أ�صا�س جمموع �لنقاط: 2-3 )�ملجموعة �الوىل( �أو 4≤ )�ملجموعة �لثانية(. ومت �حت�صاب معدل �لبقاء على قيد 
70 )%28.3( يف �ملجموعة  177 )%71.7( مري�صا يف �ملجموعة �الأوىل و  النتائج: كان هناك  �حلياة با�صتخد�م منحنيات كابالن ماير. 
�لثانية. وب�صكل عام كان عمر مر�صى �ملجموعة �الأوىل �أ�صغر بكثري مقارنة مبر�صى �ملجموعة �لثانية )متو�صط �لعمر: 35 مقابل 60 �صنة 
1:1.18، على  1:1.06 مقابل  �إىل �الإناث من  )ن�صبة �لذكور  P(، بينما كان �لتوزيع بني �جلن�صني مت�صابها يف كال �ملجموعتني   >0.001 ؛ 
�لتو�يل؛ P = 0.683(. كان د�ء �ل�صكري �العتالل �مل�صرتك �الأكرث �صيوًعا )%17(، يليه �رتفاع �صغط �لدم )%12( و�الأمر��س �مَلَعِدية �مَلَعِوية 
)%6(. مل تكن هناك فروقات ذ�ت داللة �إح�صائية يف معدل �لوفيات بني �ملجموعتني )%9.6 مقابل %8.6؛ P = 0.801(. ويف �ملجمل كان 
ما ن�صبته %69.6 من جميع �لوفيات مرتبطا بتطور �رصطان �لدم �لنخاعي �ملزمن ولي�س ب�صبب وجود �الأمر��س �مل�صاحبة. اخلال�صة: مل يتم 
�لعثور على عالقة ذ�ت داللة �إح�صائية بني جمموع نقاط معيار ت�صارل�صون لالعتالل �مل�صرتك و�لبقاء على قيد �حلياة بني مر�صى �رصطان 
�لدم �لنخاعي �ملزمن يف �لب�رصة. ومع ذلك هناك حاجة �إىل در��صات م�صتقبلية �أو�صع وطويلة �الجل لتقييم �رتباطات متو�صط �لعمر عند 
�لت�صخي�س مع �صدة �ملر�س وتطوير مقايي�س �لتنبوؤ �خلا�صة بكل منطقة.
الكلمات املفتاحية: �العتالل �مل�صرتك؛ �رصطان �لدم �لنخاعي �ملزمن؛ وفيات؛ حتليل �لبقاء على قيد �حلياة؛ �الأمر��س �ملزمنة؛ �لعر�ق.
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- Larger prospective studies are needed to confirm the findings of the current study and to evaluate the potential role of comorbidity 
treatment on survival. Such data may help in the development of region-specific prognostic scales.
Application to Patient Care
- There is no decrease in overall survival due to the presence of comorbidities among chronic myeloid leukaemia patients in Basra, Iraq, 
and patients may present at a younger age in comparison to those in Western countries.
Worldwide, chronic myeloid leukaemia (CML) accounts for approximately 15% of all types of leukaemia in adults.1 Although 
there is paucity of epidemiological data, the incidence 
of CML is usually considered similar across the 
globe.2,3 Studies from North America and Europe have 
reported an age-adjusted incidence of 0.6–2 and 0.7–1 
per 100,000 individuals, respectively.3,4 However, in 
Iraq, the age-standardised incidence of leukaemia has 
been reported as 3.9–4.3 per 100,000 individuals.5,6 
The varying prevalence and mortality rates of CML 
may be due to differences in accessibility to treatment 
options; for example, the availability of tyrosine kinase 
inhibitors (TKIs) has significantly decreased annual 
CML-related mortality rates to <2–3%.2,7 Ironically, 
however, this decrease in mortality has increased the 
prevalence of CML worldwide.2,3,8
Comorbidities are defined as distinct additional 
clinical conditions that either pre-exist or occur during 
the course of a primary disease.9 Comorbidities have a 
strong negative association with overall survival (OS) 
among patients with chronic diseases; for example, in 
cancer patients, comorbidities can affect the diagnosis, 
treatment and outcomes.10 Comorbidities can also 
increase the cost of treatment and decrease the patient’s 
quality of life.11 The presence of comorbidities has 
been shown to influence OS in chronic lymphocytic 
leukaemia (CLL).10,12 Similarly, comorbidities have also 
been reported to have a negative impact on OS among 
CML patients; however, there is no effect on treatment 
success with TKIs.13,14
The impact of comorbidities on disease outcomes 
can be measured by a well-established and validated 
20-item risk-scoring tool, the Charlson Comorbidity 
Index (CCI).15,16 This tool is based on the principle that 
age and the presence and severity of comorbidities 
increase the likelihood of mortality among patients 
who receive treatment for chronic illnesses. Scores 
for each item range from 1–6, with the maximum 
score given in the presence of a metastatic tumour 
or acquired immune deficiency syndrome; age is also 
considered a risk factor, with an additional point for 
each completed decade beyond 40 years.15
To the best of the authors’ knowledge, the use 
of prognostic scales such as the CCI has not been 
adequately studied among CML patients in Iraq and 
other Middle Eastern countries. This study aimed to 
evaluate the effect of comorbidities and age on OS 
among patients with CML treated with imatinib or 
other TKIs using the CCI.
Methods
This retrospective study was conducted between 
January 2006 and October 2016 at the Basra Oncology 
& Haematology Centre, Basra, Iraq. A total of 285 CML 
cases registered at the Basra Oncology & Haematology 
Centre during the study period were reviewed. Only 
CML patients treated with TKIs and who underwent 
regular follow-up were enrolled in the study (N = 247). 
Patients who discontinued treatment for over three 
months continuously (including pregnant women) 
and those who did not have regular follow-up visits 
during the study period were excluded at the time of 
screening.
The clinical and demographic information necess- 
ary to calculate CCI scores were extracted from the 
patients’ hospital records, including age, gender, date 
of diagnosis, duration of treatment, outcome and cause 
of death. The medical records also included a detailed 
patient history and results of a physical examination 
in addition to the initial CCI score, an essential part 
of early assessment for every patient prior to receiving 
therapy. The overall CCI scores were calculated acc- 
ording to Table 1.15 Based on their scores, patients 
were divided into two groups; those with scores of 2–3 
were assigned to the CCI1 group, while patients with 
higher scores of ≥4 were allocated to the CCI2 group.
In cases where patients had a history of past ill- 
nesses that fell within the CCI parameters (i.e. aortic 
aneurysms of ≥6 cm, dementia, chronic pulmonary 
disease or peptic ulcer disease), the previous diagnosis 
and management of the illness was reviewed with 
relevant specialists, if necessary. In order to evaluate the 
molecular response to TKI treatment, patients under- 
went regular breakpoint cluster region-Abelson murine 
leukaemia screening every six months using the 
GeneXpert® assay (Cepheid Inc., Sunnyvale, California, 
USA). In order to avoid bias, the analyst was blinded to 
the patient details.
The statistical analysis was conducted using 
Epi Info™ software, Version 3.3 (Centers for Disease 
Control and Prevention, Atlanta, Georgia, USA). The 
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cause of death was evaluated and recorded individually 
for each patient while the mortality rate was calculated 
for the overall study population. For the purposes of the 
study, OS was defined as the time between diagnosis 
and death, irrespective of the administration of TKIs. 
The OS probabilities were calculated using Kaplan-
Meier curves. A P value of <0.05 was considered stat- 
istically significant.
This study was reviewed and approved by the 
Medicine Ethical Committee of Basra College of Med- 
icine, Basra, Iraq (#569). All procedures and protocols 
involved in this study were conducted in accordance 
with the principles of the revised Declaration of Helsinki.
Results
A total of 285 CML cases were registered at the Basra 
Oncology & Haematology Centre during the study 
period; of these, 247 (86.7%) patients treated with 
TKIs and followed-up regularly were included in the 
analysis. The median age of these patients was 43.5 
years (range: 5–102 years old) and the male-to-female 
ratio was 1:1.09 [Table 2]. Based on their CCI scores, 
177 (71.7%) patients were allocated to the CCI1 group 
(i.e. those with lower CCI scores) and 70 (28.3%) to 
the CCI2 group (i.e. those with higher CCI scores). 
Patients in the CCI1 group were considerably younger 
than those in the CCI2 group (median age: 35 versus 
60 years; P <0.001). However, the gender distribution 
was similar in both groups (male-to-female ratio of 
1:1.06 versus 1:1.18; P = 0.683) [Table 3].
The median duration of follow-up was 50 months 
(range: 2–198 months). The most common comorb- 
idity was diabetes mellitus (17%), followed by hyper- 
tension (12%) and gastrointestinal disorders (6%). The 
least common comorbidities were hepatitis, neurological 
disorders and other cancers (1% each) [Figure 1]. 
Almost all (94%) of the patients were initially pres- 
cribed 400 mg of imatinib; however, 88 (38%) of which 
were later switched to 800 mg of nilotinib. In contrast, 
Table 1: Weighted scores for each item of the 20-item 
Charlson Comorbidity Index15
Item Weighting
1. Age Score of 1 for every 
decade over 40 
years of age
2. History of myocardial infarct (not 
ECG changes alone)
Score of 1 per item
3. Congestive heart failure
4. Peripheral vascular disease 
including aortic aneurysms of ≥6 cm
5. Cerebrovascular disease (i.e. 
accident with mild or no residual 
impact or a transient ischaemic 
attack)
6. Dementia
7. Chronic pulmonary disease
8. Connective tissue disease
9. Peptic ulcer disease
10. Mild liver disease without portal 
hypertension and including chronic 
hepatitis
11. Diabetes without end-organ 
damage (excluded in patients on 
dietary control alone)
12. Haemiplegia
Score of 2 per item
13. Moderate or severe renal disease
14. Diabetes with end-organ damage 
(i.e. retinopathy, neuropathy, 
nephropathy or brittle diabetes)
15. Tumour without metastasis 
(excluded if >5 years since diagnosis)
16. Leukaemia (acute or chronic)
17. Lymphoma
18. Moderate or severe liver disease Score of 3
19. Metastatic tumour
Score of 6 per item20. Acquired immune deficiency 
syndrome
ECG = electrocardiography.
Table 2: Age and gender distribution of patients with chronic 











<10 2 (1.7) 2 (1.6) 4 (1.6) 1.6
10–19 8 (6.8) 6 (4.7) 14 (5.7) 7.3
20–29 18 (15.3) 15 (11.6) 33 (13.4) 20.6
30–39 24 (20.3) 29 (22.5) 53 (21.5) 42.1
40–49 20 (16.9) 25 (19.4) 45 (18.2) 60.3
50–59 29 (24.6) 27 (20.9) 56 (22.7) 83
≥60 17 (14.4) 25 (19.4) 42 (17) 100
Table 3: Age and gender distribution according to comorb- 
idity groups of patients with chronic myeloid leukaemia in 
Basra, Iraq (N = 247)

















1:1.09 1:1.06 1:1.18 0.683
CCI = Charlson Comorbidity Index.
*As assessed using the Charlson Comorbidity Index, with patients receiving 
scores of 2–3 or ≥4 assigned to the CCI1 and CCI2 groups, respectively.15
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15 patients who were initially administered nilotinib 
continued taking it throughout the study period. 
Overall, 55.7% of patients responded to treatment; 
however, 14.9% had suboptimal results and 29.4% 
failed to respond at all. 
A total of 23 patients died during the study period, 
resulting in a mortality rate of 9.3%. The median age 
of those who died was 44 years, while the median age 
of those who survived was 43 years. Mortality rates 
were similar for patients of both genders and across 
both CCI1 and CCI2 groups [Table 4]. There was 
no significant difference in mortality according to 
the CCI score (9.6% versus 8.6%; P = 0.801). Of the 
23 deaths, analysis showed that 69.6% were related to 
CML progression, rather than comorbidity burden. 
The remaining 30.4% of deaths were due to ischaemic 
heart disease (8.7%), other cancers (8.7%; including 
one case each of transitional cell carcinoma of the 
bladder and laryngeal cancer), renal failure (4.3%), a 
cerebrovascular-related accident (4.3%) and a war 
injury (4.3%). Figure 2 shows the Kaplan-Meier 
cumulative survival curve for the two groups across 
the follow-up period.
Discussion
The CCI tool assesses the presence and severity of 
various comorbidities as parameters in the prognostic 
analysis of chronic diseases and has been utilised 
successfully among patients with a variety of 
illnesses, including CML, CLL and myelodysplastic 
syndrome.10,12,13,15 Among CML patients, clinical studies 
have utilised the CCI to evaluate the effect of comorb- 
idities on OS, event-free survival, remission rates, 
progression of the disease to accelerated phase or blast 
crisis, onset of complications, compliance to treatment 
and all-cause or cancer-specific mortality rates.13,14,17–21 
In CML, most previous studies have evaluated the 
association between CCI and survival outcomes in 
patients being treated with imatinib; however, Breccia 
et al. reported its use among those treated with other 
TKIs (i.e. dasatinib).13,14,17–21 
 
Figure 1: Frequency of comorbidities among patients with chronic myeloid leukaemia in Basra, Iraq (N = 247).
Table 4: Mortality rate according to comorbidity groups among 
patients with chronic myeloid leukaemia in Basra, Iraq (N = 247)
Group* n (%)
Dead Alive









































CCI = Charlson Comorbidity Index.
*As assessed using the Charlson Comorbidity Index, with patients receiving 
scores of 2–3 or ≥4 assigned to the CCI1 and CCI2 groups, respectively.15  
Figure 2: Kaplan-Meier survival curve showing cumulative 
survival according to comorbidity groups* among patients 
with chronic myeloid leukaemia in Basra, Iraq (N = 247).
CCI = Charlson Comorbidity Index.
*As assessed using the Charlson Comorbidity Index, with patients 
receiving scores of 2–3 or ≥4 assigned to the CCI1 and CCI2 
groups, respectively.15
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As the availability of TKIs has markedly decreased 
mortality rates among CML patients, appropriate 
information regarding risk factors or poor prognostic 
markers can help in the individualisation of therapy.7 
As such, findings from the present study may be 
helpful as a basis for the development of a modified 
risk assessment system for patients with CML in Iraq. 
Use of an appropriate prognostic scale can help in 
the appropriate selection of TKIs, proper monitoring 
during treatment and assessment of survival outcomes 
and treatment response among affected patients.7
In the present study, the median age of CML 
patients at the time of diagnosis was 43.5 years; this is 
younger in comparison to patients reported in Western 
populations.13,14,17 Similar findings have been reported 
in other Iraqi epidemiological studies; however, unlike 
the current study, these previous reports described 
CML as being more common among males than 
females.22,23 As the median age of the patient population 
was younger in the present study, CCI scoring was age-
adjusted for assessment purposes. As with previous 
studies from other countries, diabetes was found to be 
the most common comorbidity reported among CML 
patients in the current study.13,14,17,20
Previous research suggests that higher CCI scores 
are significantly associated with lower OS probabilities, 
with inverse associations noted between CCI scores 
and OS among chronic phase CML patients in Japan, 
Italy and Germany.13,14,19 Saussele et al. observed that 
higher CCI scores were significantly associated with 
lower OS probabilities (P <0.001), even after excluding 
age from the CCI calculation.13 The presence of 
comorbidities at the time of diagnosis has also been 
associated with poor survival outcomes among CML 
patients being treated with TKIs, with comorbidities 
having more impact on survival than the disease itself.12 
Similarly, Imataki et al. documented a significant log-
rank association between comorbidity at diagnosis 
and survival among CML patients on TKI treatment 
(P = 0.0136).20 Breccia et al. also reported that comor- 
bidities had a similar impact on median OS and non-
CML-related deaths.19 
In contrast, the present retrospective analysis 
did not reveal a significant difference in mortality 
rates among CML patients according to CCI scores. 
Instead, the study found that 69.6% of deaths in the 
patient population were due to CML and not the 
presence or severity of comorbidities. This was in 
contrast to the findings of Saussele et al. and Uemura et 
al., who reported that mortality among CML patients 
was more dependent on comorbidities than CML.13,14 
This difference in findings may be because of the more 
aggressive behaviour of CML among the Iraqi people. 
As such, mutational studies are recommended for 
Iraqi patients with primary and secondary failure to 
investigate the nature of CML in this population. 
Other prognostic scales available for use among 
CML patients include the Sokal Index, Hasford Risk 
Score, Karnofsky Performance Scale Index (KPSI) 
and the European Treatment and Outcome Study 
(EUTOS) score.24–26 It is likely that varying results 
regarding OS in CML patients reported by different 
studies is due to the selection of disparate prognostic 
markers and scoring systems, thereby highlighting 
the need for a uniform prognostic scoring system 
for CML patients. Of the CCI, EUTOS and KPSI 
scales, Saussele et al. found that CCI was the most 
powerful predictor for OS in German patients with 
CML.13 Similarly, the authors of the current study plan 
to compare the aforementioned prognostic scores 
among CML patients being treated with TKIs at the 
Basra Oncology & Haematology Centre. Additionally, 
further research evaluating the application of the CCI 
tool among older patients is necessary.
The limitations of the current study include its 
retrospective design, the limited sample size and the 
lack of availability of data regarding management of 
the comorbidities identified in the study population. 
Although there was no correlation between CCI and 
OS, further analysis using a larger dataset is needed to 
generate stronger evidence for this finding. Additionally, 
future studies should investigate the correlation between 
age at disease onset and patient outcome.
Conclusion
The median age of CML patients in Basra was lower 
than epidemiological data reported from other countries. 
Moreover, the CCI score was not significantly assoc- 
iated with OS; for the majority of patients, disease 
progression due to CML itself was the cause of death, 
rather than the presence or severity of comorbidities. 
Further research into the development of more accurate 
region-specific prognostic scoring systems to evaluate 
risk-based outcomes among CML patients would facili- 
tate individualised treatment for this population.
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